Tag: sk biopharmaceuticals

sk biopharmaceuticals

Latest News

28일(현지 시간) 브라질 상파울루에서 열린 '한-브라질 비즈니스 라운드테이블'에 참석한 주요 인사들. (왼쪽부터) 류진 한국경제인협회 회장, 김정관 산업통상부 장관, 이동훈 SK바이오팜 사장, 마르쿠 빌리 유로파마 글로벌 CEO, 마르시우 엘리아스 호자 브라질 개발산업통상서비스부 장관, 라우데미르 뮐러 Apex 브라질 회장. 사진 SK바이오팜=

SK Biopharmaceuticals expands Latin America push during Lee visit with epilepsy drug cenobamate

During President Lee Jae Myung’s Brazil visit, SK Biopharmaceuticals expanded its Eurofarma partnership as it prepares to launch its epilepsy treatment and broaden R&D and digital healthcare ties across Latin America.

2026.7.29

Presidential Director of National Policy Kim Yong-beom speaks during a press briefing on trariff negotiations between Korea and the United States at the presidential office in Yongsan District, central Seoul, on July 31. [NEWS1]

U.S. trade deal has pharma firms on edge despite 'most favored nation' status

Following the Korea-U.S. tariff negotiations on Wednesday, the Korean government said Washington has promised most-favored-nation (MFN) treatment under its upcoming pharmaceutical tariff policy.

2025.7.31

Most popular

Yoo Chang-ho, head of strategy at SK Biopharmaceuticals, left, and Bae Min-seok, CEO of PhnyX Lab, pose for a commemorative photo marking the signing of a memorandum of understanding on AI-based drug development at the SK Biopharmaceuticals booth during BIO USA 2025 on June 17. [SK BIOPHARMACEUTICALS]

SK Biopharma inks MOU with PhnyX Lab to create AI-powered drug development framework

SK Biopharmaceuticals signed a memorandum of understanding with PhnyX Lab, a U.S.-based AI startup backed by SK Networks, to establish an AI-powered drug development framework.

2025.6.18

SK Biopharmaceuticals CEO Lee Dong-hoon speaks at a press event on Monday announcing the joint venture formed between the Korean company and Eurofarma in San Francisco. [SK BIOPHARMACEUTICALS]

SK Biopharmaceuticals, Eurofarma to launch telehealth joint venture

SK Biopharmaceuticals and Eurofarma formed a joint venture to develop an AI platform for managing epilepsy. The focus includes real-time seizure prediction and a community for patient communication.

2025.1.15

SK Biopharmaceuticals CEO Lee Dong-hoon speaks during the 42nd J.P. Morgan Healthcare Conference held in San Francisco, California, between Jan. 8 to 11. [SK BIOPHARM]

SK Biopharmaceuticals returns to profit as epilepsy drug boosts bottom line

SK Biopharmaceuticals swung to black in the fourth quarter last year with expectation-beating results. Its annual operating loss got smaller as well, driven by strong sales of its epilepsy drug Xcopri, according to the drugmaker.

2024.1.29

SK Biopharmaceuticals (SK Biopharm) CEO Lee Dong-hoon speaks during the 42nd J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday. [SK BIOPHARM]

SK Biopharm expects turnaround year with potential 'blockbuster' drug

SK Biopharmaceuticals expects positive cash flow from the epilepsy drug Xcopri, and aims for $2 billion in sales by 2029.

2024.1.10

SK Biopharmaceuticals CEO Lee Dong-hoon speaks during a press conference held in western Seoul on Tuesday. [SK BIOPHARMACEUTICALS]

SK Biopharmaceuticals aims to become 'big biotech'

The Seongnam, Gyeonggi-based biopharmaceutical company expects to swing back into profit next year with global sales of Cenobamate, and hopes to achieve an enterprise value of $15 billion by 2026.

2023.7.18